BioPharma Credit PLC Recaptures Its Corporate Power by Buying Back Swathes of its Own Shares

BioPharma Credit PLC, the sole London-based specialist debt investor in life sciences, recently undertook several transactions to purchase its own shares. These shares were subsequently moved into the Company’s treasury, thereby consolidating the firm’s grasp on corporate control.

The shares, each valued at US$0.01, were bought through J.P. Morgan Securities plc. In a flurry of transactions conducted between March and April 2025, BioPharma Credit PLC secured a cumulative 1,245,811 of its own shares.

As a consequence of these transactions, there is now a total of 238,511,452 ordinary shares kept securely within the company ministry. In contrast, the number of issued ordinary shares, excluding those held within the treasury, stands at 1,135,420,615. These figures aid in mapping out the total voting rights within the Company, a factor that shareholders may find useful for calculations regarding their interests in BioPharma Credit PLC.

BioPharma Credit PLC continues its seamless operation, dedicated to fulfilling its primary objective of delivering sustainable income distributions from exposure to the life sciences industry. With the recent transaction set to bolster the firm’s hold and maximize its power within its own corporate landscape, the company sets an example of the ideal blend between financial prudence and strategic corporate management.